This HTML5 document contains 152 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
n11http://dbpedia.org/resource/File:
foafhttp://xmlns.com/foaf/0.1/
n7https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n10http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Discovery_and_development_of_direct_Xa_inhibitors
rdfs:label
Discovery and development of direct Xa inhibitors
rdfs:comment
Four drugs from the class of direct Xa inhibitors are marketed worldwide. Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. The second one was apixaban (Eliquis), approved in Europe in 2011 and in the United States in 2012. The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. Betrixaban (Bevyxxa) was approved in the US in 2017.
foaf:depiction
n10:Rivaroxaban_binding_pocket_sites_vizualized.png n10:Rivaroxaban_1st_SAR.svg n10:Coagulation_in_vivo.png n10:Heparin_General_Structure_V.1.svg n10:PDB_1skz_EBI.jpg n10:Protein_F10_PDB_1c5m.png n10:Dirext_Xa-inhibitor_Prototypes_YM-60828_(left)_and_DX-9065a_(right).jpg n10:Apixaban_Sar_13f.png n10:Apixaban_binding_sites_pockets.png n10:Apixaban_SAR.svg n10:Xa_inhibitors_rotated.svg n10:Warfarin.svg
dcterms:subject
dbc:Drug_discovery dbc:Direct_Xa_inhibitors
dbo:wikiPageID
51714214
dbo:wikiPageRevisionID
1064283681
dbo:wikiPageWikiLink
dbr:Atrial_fibrillation dbr:Substrate_(chemistry) dbr:Rivaroxaban dbr:Phosgene dbr:Pyrazole dbr:Tetrazole dbr:Drug_compliance dbr:William_Henry_Howell dbr:Leech dbr:Thrombin_inhibitor_(disambiguation) dbr:Anticoagulant_drug dbr:Arginine dbr:Heparin dbr:Amine dbr:Thiophene dbr:Arylation n11:Apixaban_Sar_13f.png n11:Apixaban_binding_sites_pockets.png dbr:Clinical_trials dbr:Pfizer dbr:Protecting_group dbr:Volume_of_distribution dbr:2-Oxazolidone n11:Apixaban_SAR.svg dbr:Hemostasis dbr:Coagulation dbr:2-oxazolidinone dbr:2-oxazolidone dbr:Tyramine dbr:Low_molecular_weight_heparin n11:Xa_inhibitors_rotated.svg dbr:Alkylated dbr:Decoy_receptor dbr:2-Piperidinone dbr:Karl_Paul_Link dbr:Iodine dbr:Homology_(biology) dbr:Morpholine n11:Coagulation_in_vivo.png dbr:Patent dbr:Venous_thromboembolism dbr:Antidote n11:Protein_F10_PDB_1c5m.png dbr:Rodenticide dbr:Deep_vein_thrombosis dbr:Pharmacokinetic dbr:Recombinant_protein dbr:Copper dbr:Aminolysis dbr:Saccharomyces_cerevisiae dbr:Thrombosis dbr:High-throughput_screening dbr:Portola_Pharmaceuticals dbr:Phthalimide dbr:Edoxaban dbr:C-term dbr:Half-life dbr:Betrixaban dbr:Amino_group dbr:Apixaban dbr:Nitrogen dbr:Cystein dbr:Bayer dbr:Carbamate dbr:Structure-activity_relationship dbr:Carbonyl_group dbr:Amide dbr:Ornithodoros_moubata dbr:Bayer_Healthcare dbr:Alcohol_(chemistry) dbr:Elimination_reaction dbr:Acetamide dbr:Bioavailability dbr:Amidine dbr:Solvents dbr:Trypsin dbr:Tedizolid dbr:Propylene_oxide dbr:Perpendicular dbr:Small_molecules n11:PDB_1skz_EBI.jpg dbr:Aspartic_acid dbr:Pulmonary_embolism dbr:LMWH dbr:Linezolid dbr:Acylation dbr:Epidermal_growth_factor dbr:N-term dbr:Dicoumarol dbr:Warfarin dbr:Fibrinogen dbr:Gla_domain n11:Warfarin.svg dbc:Drug_discovery dbr:Internal_bleeding dbr:Hydrogen_chloride n11:Dirext_Xa-inhibitor_Prototypes_YM-60828_(left)_and_DX-9065a_(right).jpg dbr:Cycloaddition dbr:Silyl_ether dbr:Andexanet_alfa n11:Rivaroxaban_Synthesis_as_patented_by_Bayer.tif n11:Rivaroxaban_binding_pocket_sites_vizualized.png dbr:Fibrin dbc:Direct_Xa_inhibitors dbr:Benzene n11:Rivaroxaban_1st_SAR.svg dbr:Salivary_glands dbr:Prothrombin dbr:Daiichi_Sankyo dbr:Enzyme_inhibitor dbr:Endothelium dbr:Hepar dbr:Therapeutic_window dbr:Antibiotic dbr:Atherosclerosis dbr:Carboxylic_acid dbr:Jay_McLean n11:Synthesis_of_Apixaban_as_described_by_Pinto_et.al.tif dbr:Disulfide dbr:Drug_target dbr:Intravenously dbr:Subcutaneously dbr:IC50 n11:Heparin_General_Structure_V.1.svg
owl:sameAs
n7:2cyfg wikidata:Q28209258
dbp:wikiPageUsesTemplate
dbt:Reflist dbt:Drug_design
dbo:thumbnail
n10:Heparin_General_Structure_V.1.svg?width=300
dbo:abstract
Four drugs from the class of direct Xa inhibitors are marketed worldwide. Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. The second one was apixaban (Eliquis), approved in Europe in 2011 and in the United States in 2012. The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. Betrixaban (Bevyxxa) was approved in the US in 2017.
prov:wasDerivedFrom
wikipedia-en:Discovery_and_development_of_direct_Xa_inhibitors?oldid=1064283681&ns=0
dbo:wikiPageLength
41915
foaf:isPrimaryTopicOf
wikipedia-en:Discovery_and_development_of_direct_Xa_inhibitors
Subject Item
wikipedia-en:Discovery_and_development_of_direct_Xa_inhibitors
foaf:primaryTopic
dbr:Discovery_and_development_of_direct_Xa_inhibitors